Related Experiment Video

Updated: Dec 29, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K

Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma

Diana Basali1, Rajshekhar Chakraborty2, Lisa Rybicki2

  • 1Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.

British Journal of Haematology
|February 4, 2020
PubMed

Insights

Venetoclax shows promise for relapsed/refractory multiple myeloma (RRMM), particularly in t(11;14) patients. This study found a 78% response rate with manageable toxicities in RRMM patients treated with venetoclax-based regimens.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Relapsed/refractory multiple myeloma (RRMM) presents significant treatment challenges.
  • Venetoclax, a BCL-2 inhibitor, offers a novel therapeutic approach.
  • The t(11;14) translocation is a key indicator for venetoclax efficacy.

Purpose of the Study:

  • To evaluate the clinical experience with venetoclax-based regimens in RRMM patients.
  • To assess the efficacy and safety of venetoclax in a real-world setting.
  • To identify patient characteristics associated with treatment response.

Main Methods:

  • Retrospective review of ten RRMM patients treated with venetoclax.
  • Analysis of prior treatment lines, overall response rate (ORR), and toxicities.
  • Inclusion of patients with and without t(11;14) translocation.

Main Results:

  • An overall response rate of 78% was observed in the RRMM cohort.
  • One patient with cardiac amyloidosis and multiple myeloma (MM) achieved a cardiac organ response.
  • Common toxicities included hematologic issues and gastrointestinal upset.

Conclusions:

  • Venetoclax-based regimens demonstrate significant efficacy in heavily pretreated RRMM patients.
  • Venetoclax is a viable treatment option, especially for patients with the t(11;14) translocation.
  • Careful monitoring for hematologic and non-hematologic toxicities is essential.
Keywords:
amyloidamyloidosisrelapsed/refractory multiple myelomatranslocationvenetoclax

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

568
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
167
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.5K
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
213
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
140
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K